Logo image of ALCOX.PA

NICOX SA (ALCOX.PA) Stock Fundamental Analysis

EPA:ALCOX - Euronext Paris - Matif - FR0013018124 - Common Stock - Currency: EUR

0.624  +0.1 (+19.54%)

Fundamental Rating

2

Taking everything into account, ALCOX scores 2 out of 10 in our fundamental rating. ALCOX was compared to 73 industry peers in the Biotechnology industry. ALCOX has a bad profitability rating. Also its financial health evaluation is rather negative. ALCOX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ALCOX has reported negative net income.
ALCOX had negative earnings in each of the past 5 years.
ALCOX had a negative operating cash flow in each of the past 5 years.
ALCOX.PA Yearly Net Income VS EBIT VS OCF VS FCFALCOX.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

ALCOX has a Return On Assets of -92.83%. This is in the lower half of the industry: ALCOX underperforms 73.97% of its industry peers.
ALCOX's Return On Equity of -653.37% is on the low side compared to the rest of the industry. ALCOX is outperformed by 73.97% of its industry peers.
Industry RankSector Rank
ROA -92.83%
ROE -653.37%
ROIC N/A
ROA(3y)-53.69%
ROA(5y)-42.4%
ROE(3y)-266.03%
ROE(5y)-174.79%
ROIC(3y)N/A
ROIC(5y)N/A
ALCOX.PA Yearly ROA, ROE, ROICALCOX.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

ALCOX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALCOX.PA Yearly Profit, Operating, Gross MarginsALCOX.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K -100K

More info and screens

3

2. Health

2.1 Basic Checks

ALCOX has more shares outstanding than it did 1 year ago.
ALCOX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ALCOX has a worse debt to assets ratio.
ALCOX.PA Yearly Shares OutstandingALCOX.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ALCOX.PA Yearly Total Debt VS Total AssetsALCOX.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

ALCOX has an Altman-Z score of -33.44. This is a bad value and indicates that ALCOX is not financially healthy and even has some risk of bankruptcy.
ALCOX has a worse Altman-Z score (-33.44) than 87.67% of its industry peers.
ALCOX has a Debt/Equity ratio of 4.40. This is a high value indicating a heavy dependency on external financing.
ALCOX has a worse Debt to Equity ratio (4.40) than 71.23% of its industry peers.
Industry RankSector Rank
Debt/Equity 4.4
Debt/FCF N/A
Altman-Z -33.44
ROIC/WACCN/A
WACCN/A
ALCOX.PA Yearly LT Debt VS Equity VS FCFALCOX.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 5.85 indicates that ALCOX has no problem at all paying its short term obligations.
ALCOX has a better Current ratio (5.85) than 79.45% of its industry peers.
ALCOX has a Quick Ratio of 5.85. This indicates that ALCOX is financially healthy and has no problem in meeting its short term obligations.
ALCOX has a better Quick ratio (5.85) than 80.82% of its industry peers.
Industry RankSector Rank
Current Ratio 5.85
Quick Ratio 5.85
ALCOX.PA Yearly Current Assets VS Current LiabilitesALCOX.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 23.81% over the past year.
ALCOX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.86%.
ALCOX shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.77% yearly.
EPS 1Y (TTM)23.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)13.86%
Revenue growth 3Y2.81%
Revenue growth 5Y2.77%
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
The Revenue is expected to grow by 102.03% on average over the next years. This is a very strong growth
EPS Next Y16%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year318.37%
Revenue Next 2Y102.03%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ALCOX.PA Yearly Revenue VS EstimatesALCOX.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M 20M
ALCOX.PA Yearly EPS VS EstimatesALCOX.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -0.5 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ALCOX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ALCOX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALCOX.PA Price Earnings VS Forward Price EarningsALCOX.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALCOX.PA Per share dataALCOX.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 -0.2 -0.3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ALCOX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NICOX SA

EPA:ALCOX (8/7/2025, 7:00:00 PM)

0.624

+0.1 (+19.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-23 2025-07-23
Earnings (Next)10-15 2025-10-15
Inst Owners6.33%
Inst Owner ChangeN/A
Ins Owners0.13%
Ins Owner ChangeN/A
Market Cap45.23M
Analysts84.44
Price Target1.02 (63.46%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.75
P/FCF N/A
P/OCF N/A
P/B 15.08
P/tB 15.13
EV/EBITDA N/A
EPS(TTM)-0.31
EYN/A
EPS(NY)-0.22
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.11
BVpS0.04
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -92.83%
ROE -653.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-53.69%
ROA(5y)-42.4%
ROE(3y)-266.03%
ROE(5y)-174.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.33
Health
Industry RankSector Rank
Debt/Equity 4.4
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.85
Quick Ratio 5.85
Altman-Z -33.44
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y16%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)13.86%
Revenue growth 3Y2.81%
Revenue growth 5Y2.77%
Sales Q2Q%N/A
Revenue Next Year318.37%
Revenue Next 2Y102.03%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-101.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year67.32%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A